1. Home
  2. KALA
  3. Earnings

AI Earnings Predictions for KALA BIO Inc. (KALA)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+1361.56%

$2.59

100% positive prob.

5-Day Prediction

+1366.91%

$2.60

100% positive prob.

20-Day Prediction

+1285.64%

$2.46

95% positive prob.

Price at prediction: $0.18 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +1361.56% +1366.91% +1285.64% 100.0% Pending
Q2 2025 SELL -2.50% -9.43% -11.50% 99.7% +12.74%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 9, 2026 · 100% conf.

AI Prediction BUY

1D

+1361.56%

$2.59

Act: -3.38%

5D

+1366.91%

$2.60

20D

+1285.64%

$2.46

Price: $0.18 Prob +5D: 100% AUC: 1.000
0001829126-26-012118

EX-99.1

2 kalabio_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

KALA

BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results

New York, November 9, 2026 – KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026.

Preliminary Third Quarter 2026 Results

●Net loss of approximately $0.8 million for the third quarter of 2026, compared to $7.6 million for the third quarter of 2025.

●Net loss of approximately $4.0 million for the nine months ended September 30, 2026, compared to $27.7 million for the same period in 2025.

●Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt.

“We reduced our quarterly net loss by approximately 90% year over year and continue to develop the initiatives we have put in motion. We thank our stockholders who attended our Annual Meeting on November 3, 2026, and for their continued support,” said Avi Minkowitz, Chief Executive Officer and Chief Financial Officer.

KALA

expects to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 with the SEC on or about November 16, 2026.

Preliminary Results

The results above are preliminary, unaudited and subject to completion of the Company’s financial close procedures and review by its independent registered public accounting firm. Final results, to be included in the Form 10-Q, may differ.

About Kala Bio, Inc. (NASDAQ: KALA)

KALA

BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business that deploys secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.

Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.

Kala believes the future of biomedical innovation is in agentic systems.

For more information, visit www.kalarx.com and Researgency.ai

Forward-Looking

Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s preliminary unaudited financial results for the three and nine months ended September 30, 2026 and the expected timing of the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

The preliminary financial results set forth in this press release are based on management’s current estimates and information available as of the date of this release. They are unaudited and remain subject to the completion of the Company’s financial closing procedures, final adjustments, and review by the Company’s independent registered public accounting firm. The Company’s actual results may differ materially from these preliminary results, and these preliminary results should not be viewed as a substitute for the full interim financial statements to be included in the Form 10-Q.

Important factors that could cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to: adjustments arising from the completion of the Company’s financial closing procedures or the review of its interim financial statements; the identification of subsequent events or additional information prior to the filing of the Form 10-Q; delays in the completion or filing of the Form 10-Q; and other risks detailed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as may be updated in the Company’s Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.

Forward-looking

statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Avi Minkowitz

Chief Executive Officer, KALA BIO, Inc.

am@kalarx.c

2025
Q2

Q2 2025 Earnings

8-K SELL

Aug 8, 2025 · 100% conf.

AI Prediction SELL

1D

-2.50%

$7.20

Act: -3.25%

5D

-9.43%

$6.68

Act: +12.74%

20D

-11.50%

$6.53

Price: $7.38 Prob +5D: 0% AUC: 1.000
0001558370-25-010850

0001479419false00014794192025-08-082025-08-08 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025

KALA BIO, Inc. (Exact Name of Registrant as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On August 8, 2025, KALA BIO, Inc. announced its financial results for the quarter ended June 30, 2025 and provided a general business and corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated August 8, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: August 8, 2025 By: /s/ Mary Reumuth

Mary Reumuth

Chief Financial Officer and Corporate Secretary

​ ​ ​ ​

2025
Q1

Q1 2025 Earnings

8-K

May 14, 2025

0001558370-25-007664

0001479419false00014794192025-05-142025-05-14 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025

KALA BIO, Inc. (Exact Name of Registrant as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On May 14, 2025, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2025 and provided a general business and corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated May 14, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: May 14, 2025 By: /s/ Mary Reumuth

Mary Reumuth

Chief Financial Officer and Corporate Secretary

​ ​ ​ ​

About KALA BIO Inc. (KALA) Earnings

This page provides KALA BIO Inc. (KALA) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on KALA's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: